Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensive Pharmacokinetic Study of Three Doses of Rifapentine (600, 900 and 1200mg) During Continuation Phase Therapy of Tuberculosis in HIV-Negative Adults

NCT00023387 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT00023387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00023387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensive Pharmacokinetic Study of Three Doses of Rifapentine (600, 900 and 1200mg) During Continuation Phase Therapy of Tuberculosis in HIV-Negative Adults
Lead sponsor
Centers for Disease Control and Prevention
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2000
Completion date
May 31, 2001
Enrollment
36
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis